AU774841B2 - Development of novel anti-microbial agents based on bacteriophage genomics - Google Patents

Development of novel anti-microbial agents based on bacteriophage genomics Download PDF

Info

Publication number
AU774841B2
AU774841B2 AU15815/00A AU1581500A AU774841B2 AU 774841 B2 AU774841 B2 AU 774841B2 AU 15815/00 A AU15815/00 A AU 15815/00A AU 1581500 A AU1581500 A AU 1581500A AU 774841 B2 AU774841 B2 AU 774841B2
Authority
AU
Australia
Prior art keywords
bacteriophage
bacterial
protein
phage
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU15815/00A
Other languages
English (en)
Other versions
AU1581500A (en
Inventor
Michael Dubow
Philippe Gros
Jerry Pelletier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targanta Therapeutics Inc
Original Assignee
Targanta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/407,804 external-priority patent/US6982153B1/en
Application filed by Targanta Therapeutics Inc filed Critical Targanta Therapeutics Inc
Publication of AU1581500A publication Critical patent/AU1581500A/en
Application granted granted Critical
Publication of AU774841B2 publication Critical patent/AU774841B2/en
Assigned to TARGANTA THERAPEUTICS INC. reassignment TARGANTA THERAPEUTICS INC. Request to Amend Deed and Register Assignors: PHAGETECH, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU15815/00A 1998-12-03 1999-12-03 Development of novel anti-microbial agents based on bacteriophage genomics Ceased AU774841B2 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US11099298P 1998-12-03 1998-12-03
US60/110992 1998-12-03
US32614499A 1999-06-03 1999-06-03
US09/326144 1999-06-03
US09/407,804 US6982153B1 (en) 1998-12-03 1999-09-28 DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US09/407804 1999-09-28
US15721899P 1999-09-30 1999-09-30
US60/157218 1999-09-30
US16877799P 1999-12-01 1999-12-01
US60/168777 1999-12-01
US09/454252 1999-12-02
US09/454,252 US6783930B1 (en) 1998-12-03 1999-12-02 Development of novel anti-microbial agents based on bacteriophage genomics
PCT/IB1999/002040 WO2000032825A2 (en) 1998-12-03 1999-12-03 Development of anti-microbial agents based on bacteriophage genomics

Publications (2)

Publication Number Publication Date
AU1581500A AU1581500A (en) 2000-06-19
AU774841B2 true AU774841B2 (en) 2004-07-08

Family

ID=27557794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15815/00A Ceased AU774841B2 (en) 1998-12-03 1999-12-03 Development of novel anti-microbial agents based on bacteriophage genomics

Country Status (5)

Country Link
EP (1) EP1135535A2 (de)
JP (1) JP2002531107A (de)
AU (1) AU774841B2 (de)
CA (1) CA2353563A1 (de)
WO (1) WO2000032825A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101969B1 (en) 1998-12-03 2006-09-05 Targanta Therapeutics Compositions and methods involving an essential Staphylococcus aureus gene and its encoded protein
WO2002044718A2 (en) * 2000-11-30 2002-06-06 Phagetech Inc. S.aureus protein staau r2, gene encoding it and uses thereof
CA2396674C (en) * 1999-12-22 2006-07-04 Phagetech, Inc. Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein
CA2433386C (en) 2000-12-19 2006-11-21 Targanta Therapeutics Inc. Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9
WO2002050106A2 (en) * 2000-12-20 2002-06-27 Phagetech Inc. Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r4
WO2003024410A2 (en) * 2001-09-21 2003-03-27 New Horizons Diagnostics Corporation Composition for treating streptococcus pneumoniae
US6759229B2 (en) 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
US7442783B2 (en) * 2004-03-01 2008-10-28 The Cbr Institute For Biomedical Research, Inc. Natural IgM antibodies and inhibitors thereof
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
GB201119167D0 (en) * 2011-11-07 2011-12-21 Novolytics Ltd Novel bachteriophages
WO2014165115A1 (en) 2013-03-12 2014-10-09 Decimmune Therapeutics, Inc. Humanized anti-n2 antibodies
CN111316999B (zh) * 2020-03-04 2022-02-08 苏州十一方生物科技有限公司 一种含有噬菌体的喷雾型环境消毒剂及其制备方法和应用
CN111296493A (zh) * 2020-03-09 2020-06-19 苏州十一方生物科技有限公司 一种噬菌体消毒剂及其制备方法
EP4731683A1 (de) 2023-06-20 2026-04-29 Topaz Biosciences, Inc. Rekombinante zellwandhydrolasen
CN118240771A (zh) * 2024-03-12 2024-06-25 武汉格瑞农生物科技有限公司 一株可提升鸭疫里默氏杆菌药物敏感性的噬菌体及其应用
CN121427968B (zh) * 2026-01-04 2026-04-10 湖南师范大学 一种气单胞菌噬菌体重组系统、表达载体、重组菌株及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072925A2 (de) * 1981-08-17 1983-03-02 Rutgers Research and Educational Foundation T4-DNS-Fragment als Stabilisator für Proteine exprimiert durch kloniertes DNS
WO1989000199A1 (en) * 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Therapeutic antimicrobial polypeptides, their use and methods for preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027043A1 (en) * 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
DK0748871T3 (da) * 1995-06-16 2003-11-24 Nestle Sa Bakteriofagresistent Streptococcus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072925A2 (de) * 1981-08-17 1983-03-02 Rutgers Research and Educational Foundation T4-DNS-Fragment als Stabilisator für Proteine exprimiert durch kloniertes DNS
WO1989000199A1 (en) * 1987-07-06 1989-01-12 Louisiana State University Agricultural And Mechan Therapeutic antimicrobial polypeptides, their use and methods for preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOL. BICROBIOL. (1997) 25, PP 717-25 *

Also Published As

Publication number Publication date
WO2000032825A2 (en) 2000-06-08
AU1581500A (en) 2000-06-19
JP2002531107A (ja) 2002-09-24
EP1135535A2 (de) 2001-09-26
WO2000032825A3 (en) 2001-01-18
CA2353563A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
US6783930B1 (en) Development of novel anti-microbial agents based on bacteriophage genomics
AU774841B2 (en) Development of novel anti-microbial agents based on bacteriophage genomics
US6638718B1 (en) Methods of screening for compounds active on staphylococcus aureus target genes
KR102003770B1 (ko) 신규한 포도상구균 특이 박테리오파지 sa3 및 이를 포함하는 항균 조성물
KR101592177B1 (ko) 대장균에 대한 광범위 항균 활성을 갖는 박테리오파지를 활용한 대장균 감염을 방지 및 처치하는 방법
CN107208068B (zh) 新型产志贺毒素F18型大肠杆菌噬菌体Esc-COP-1及其用于抑制产志贺毒素F18型大肠杆菌增殖的用途
CN109082414B (zh) 一种金黄色葡萄球菌噬菌体及应用
CN114107220B (zh) 噬菌体疗法
AU2025203392A1 (en) Therapeutic bacteriophage compositions
KR101993123B1 (ko) 신규한 병원성 대장균 특이 박테리오파지 eco5 및 이를 포함하는 항균 조성물
KR20180068294A (ko) 신규한 병원성 대장균 특이 박테리오파지 ec10 및 이를 포함하는 항균 조성물
KR102432624B1 (ko) 신규한 스타필로코커스균 특이 박테리오파지 opt-sc01 및 이를 포함하는 항균 조성물
US6376652B1 (en) Compositions and methods involving an essential Staphylococcus aureus gene and its encoded protein
KR102723118B1 (ko) 스타필로코커스균 특이 박테리오파지 kmsp1 및 이를 포함하는 항균 조성물
AU778782B2 (en) Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein
KR102418861B1 (ko) 포도상구균에 대한 사멸능을 갖는 박테리오파지
US20070059709A1 (en) Staphylococcus aureus antibacterial target genes
KR102203675B1 (ko) 신규한 여시니아균 특이 박테리오파지 ye12 및 이를 포함하는 항균 조성물
US20030138771A1 (en) DNA sequences from S. pneumoniae bacteriophage DP1 that encode anti-microbal polypeptides
KR102334893B1 (ko) 신규한 캠필로박터균 특이 박테리오파지 opt-cj1 및 이를 포함하는 항균 조성물
KR20180074578A (ko) 신규한 장알균 특이 박테리오파지 ef1 및 이를 포함하는 항균 조성물
KR101993125B1 (ko) 신규한 esbl 생성 대장균 특이 박테리오파지 eco4 및 이를 포함하는 항균 조성물
KR101992013B1 (ko) 병원성 장내세균에 대해 사멸능을 갖는 신규 박테리오파지 및 이의 용도
KR102066898B1 (ko) 신규한 장알균 특이 박테리오파지 ef5 및 이를 포함하는 항균 조성물
HK40083362A (en) Bacteriophage compositions for treating staphylococcus infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 14, NO 37, PAGE(S) 6637-6641 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 15815/00

FGA Letters patent sealed or granted (standard patent)